-
Case Reports
[Subendocardial injury with no evidence of atherosclerosis associated with obinutuzumab infusion].
- Ignacio M Santarelli, Eduardo A Ibaceta Alaniz, Constanza P Cabo, Bruno Guarino, Gregorio Cordini, Sofía I Fernández, and Marcelo J Melero.
- Departamento de Medicina, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Argentina. E-mail: isantarelli@fmed.uba.ar.
- Medicina (B Aires). 2021 Jan 1; 81 (6): 1052-1055.
AbstractObinutuzumab is a fully humanized monoclonal antibody against CD20 used in the treatment of chronic lymphocytic leukemia. Fatal cardiovascular events have been described, but only in patients with known cardiovascular records. We report the case of an adult male with a high-risk chronic lymphocytic leukemia who developed subendocardial injury, with no evidence of coronary atherosclerosis, during the first administration of obinutuzumab.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..